Last reviewed · How we verify
ASP0456
ASP0456 is a small molecule inhibitor of the CDK9 enzyme.
ASP0456 is a small molecule inhibitor of the CDK9 enzyme. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma.
At a glance
| Generic name | ASP0456 |
|---|---|
| Also known as | linaclotide, Linaclotide |
| Sponsor | Astellas Pharma Inc |
| Drug class | CDK9 inhibitor |
| Target | CDK9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CDK9 inhibition is a strategy to block the transcriptional elongation process, which is crucial for the proliferation of cancer cells. By inhibiting CDK9, ASP0456 aims to suppress the growth of cancer cells and induce apoptosis.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma
- Relapsed or refractory follicular lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- "Efficacy and Safety of Linaclotide in Chronic Constipation" (PHASE4)
- Linaclotide for Colonoscopy Bowel Prep (PHASE1, PHASE2)
- A Study of Virtual Reality and Linaclotide for IBS-C (NA)
- Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide (PHASE2)
- GCC Agonist Signal in the Small Intestine (PHASE1)
- Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer (PHASE2)
- A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP0456 CI brief — competitive landscape report
- ASP0456 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI